Argenx’s Vyvgart clears Phase 3 in new subset of myasthenia gravis patientsnews2025-08-25T17:37:23+00:00August 25th, 2025|Endpoints News|
BeOne to get $885M upfront in royalty deal over Amgen’s Imdelltranews2025-08-25T16:02:36+00:00August 25th, 2025|Endpoints News|
MannKind to buy scPharmaceuticals for up to $360M; Arnatar launches with $52Mnews2025-08-25T15:08:15+00:00August 25th, 2025|Endpoints News|
Akeso touts Phase 3 wins for two separate inflammatory drugsnews2025-08-25T15:02:31+00:00August 25th, 2025|Endpoints News|
AbbVie to buy psychedelic drug from partner Gilgameshnews2025-08-25T14:56:10+00:00August 25th, 2025|Endpoints News|
Merck looks to modest HIV business as a $5B underdognews2025-08-25T14:15:34+00:00August 25th, 2025|Endpoints News|
FDA suspends license for Valneva’s chikungunya vaccine amid safety concernsnews2025-08-25T12:18:59+00:00August 25th, 2025|Endpoints News|
LB Pharmaceuticals seeks IPO as cash runs dry for looming Phase 3 schizophrenia trialnews2025-08-25T12:11:48+00:00August 25th, 2025|Endpoints News|
Viking’s obesity readout; George Church lab closer to creating human eggs; Skyhawk gets new pharma partnernews2025-08-23T10:00:09+00:00August 23rd, 2025|Endpoints News|
LB Pharmaceuticals is said to be working on IPO for schizophrenia drugnews2025-08-22T17:49:44+00:00August 22nd, 2025|Endpoints News|
